ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Washington, DC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Squamous Cell Carcinoma
Lung Cancer

Melanoma trials near Washington, DC, USA:

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...

Enrolling
Melanoma
Unresectable Melanoma
Biological: Pembrolizumab with Optional Crossover Period
Biological: Lifileucel plus Pembrolizumab

Phase 3

Iovance Biotherapeutics

Bethesda, Maryland, United States and 36 other locations

(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...

Enrolling
Melanoma
Drug: EU-authorized Nivolumab
Drug: ABP 206

Phase 3

Amgen
Amgen

Baltimore, Maryland, United States and 112 other locations

cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of...

Enrolling
Mucosal Melanoma
Melanoma
Drug: Phase 1b: APG-115+pembrolizumab

Phase 1, Phase 2

Ascentage Pharma Group
Ascentage Pharma Group

Washington, District of Columbia, United States and 20 other locations

assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma...

Enrolling
Melanoma
Drug: ABP 206
Drug: Nivolumab

Phase 3

Amgen
Amgen

Baltimore, Maryland, United States and 100 other locations

of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma...

Enrolling
Melanoma (Skin)
Metastatic Melanoma
Drug: Ipilimumab
Drug: ANV419

Phase 1, Phase 2

Anaveon

Fairfax, Virginia, United States and 24 other locations

of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma ...

Active, not recruiting
Melanoma
Biological: Durvalumab
Drug: Ceralasertib

Phase 2

AstraZeneca
AstraZeneca

Lutherville-Timonium, Maryland, United States and 65 other locations

patients with unresectable Stage III or IV melanoma. The contributions of BNT111 and cemiplimab will be delineated in single agent...

Active, not recruiting
Melanoma Stage IV
Melanoma Stage III
Biological: BNT111
Biological: Cemiplimab

Phase 2

BioNTech
BioNTech

Fairfax, Virginia, United States and 52 other locations

(Spartalizumab (PDR001)), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma...

Active, not recruiting
Melanoma
Drug: Trametinib
Drug: Dabrafenib

Phase 3

Novartis
Novartis

Lutherville, Maryland, United States and 178 other locations

to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...

Active, not recruiting
Melanoma
Biological: Nivolumab
Biological: Nivolumab + Relatlimab Fixed Dose Combination

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Washington, District of Columbia, United States and 171 other locations

treatment of adult subjects with completely treated high-risk ocular melanoma, as defined in eligibility criteria, without evidence of metas...

Active, not recruiting
Melanoma
Ocular Melanoma
Drug: Ipilimumab
Drug: Nivolumab

Phase 2

Suthee Rapisuwon

Washington, District of Columbia, United States and 5 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems